Andrey Tolkachev
Neumora Therapeutics (NMRA) has updated terms for a proposed $250M initial public offering.
The psychiatric drug developer said in an SEC filing that it was now interested in offering 14.7M shares priced between $16 and $18, which would raise around $250M if priced at the midpoint. Underwriters would be granted a 30-day option to buy up to 2.2M additional shares to cover over-allotments.
Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners.
Based in Watertown, Mass., Neumora’s lead drug candidate is navacaprant, or NMRA-140, which is entering pivotal Phase 3 testing for major depressive disorder. The company expects to release topline results from the study in the second half of 2024.
Neumora first filed for the IPO in August.
